WO2002083110A3 - Animal model for evaluating analgesics - Google Patents

Animal model for evaluating analgesics Download PDF

Info

Publication number
WO2002083110A3
WO2002083110A3 PCT/IB2002/001140 IB0201140W WO02083110A3 WO 2002083110 A3 WO2002083110 A3 WO 2002083110A3 IB 0201140 W IB0201140 W IB 0201140W WO 02083110 A3 WO02083110 A3 WO 02083110A3
Authority
WO
WIPO (PCT)
Prior art keywords
analgesics
animal model
evaluating
nsaid
trauma
Prior art date
Application number
PCT/IB2002/001140
Other languages
French (fr)
Other versions
WO2002083110A2 (en
Inventor
Fakhreddin Jamali
Original Assignee
Zagros Pharma Inc
Fakhreddin Jamali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zagros Pharma Inc, Fakhreddin Jamali filed Critical Zagros Pharma Inc
Priority to PCT/IB2002/001140 priority Critical patent/WO2002083110A2/en
Priority to EP02727818A priority patent/EP1379226A2/en
Priority to AU2002258013A priority patent/AU2002258013A1/en
Priority to CA002455274A priority patent/CA2455274A1/en
Publication of WO2002083110A2 publication Critical patent/WO2002083110A2/en
Publication of WO2002083110A3 publication Critical patent/WO2002083110A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is an animal model for testing the effectiveness of analgesics, such as NSAID, formulations or any other medicament administered for acute pain or trauma.
PCT/IB2002/001140 2001-04-10 2002-04-10 Animal model for evaluating analgesics WO2002083110A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/IB2002/001140 WO2002083110A2 (en) 2001-04-10 2002-04-10 Animal model for evaluating analgesics
EP02727818A EP1379226A2 (en) 2001-04-10 2002-04-10 Animal model for evaluating analgesics
AU2002258013A AU2002258013A1 (en) 2001-04-10 2002-04-10 Animal model for evaluating analgesics
CA002455274A CA2455274A1 (en) 2001-04-10 2002-04-10 Animal model for evaluating analgesics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28249701P 2001-04-10 2001-04-10
US60/282,497 2001-04-10
PCT/IB2002/001140 WO2002083110A2 (en) 2001-04-10 2002-04-10 Animal model for evaluating analgesics

Publications (2)

Publication Number Publication Date
WO2002083110A2 WO2002083110A2 (en) 2002-10-24
WO2002083110A3 true WO2002083110A3 (en) 2003-10-16

Family

ID=26318637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/001140 WO2002083110A2 (en) 2001-04-10 2002-04-10 Animal model for evaluating analgesics

Country Status (1)

Country Link
WO (1) WO2002083110A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050445A1 (en) * 2003-10-30 2005-06-18 Bayer Consumer Care Ag PRESENTATION FORM OF SODIUM NAPROXEN

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DRESSMAN J B ET AL: "Gastrointestinal parameters that influence oral medications.", JOURNAL OF PHARMACEUTICAL SCIENCES. UNITED STATES SEP 1993, vol. 82, no. 9, September 1993 (1993-09-01), pages 857 - 872, XP002247244, ISSN: 0022-3549 *
HARUTA SHUNJI ET AL: "Absorption behavior of orally administered drugs in rats treated with propantheline.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 87, no. 9, 1998, pages 1081 - 1085, XP002247242, ISSN: 0022-3549 *
JAMALI FAKHREDDIN ET AL: "Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 4, April 1999 (1999-04-01), pages 391 - 396, XP002247241, ISSN: 0306-5251 *
JOEL SIMON P ET AL: "Pharmacological attempts to improve the bioavailability of oral etoposide.", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 37, no. 1-2, 1995, pages 125 - 133, XP002247243, ISSN: 0344-5704 *
See also references of EP1379226A2 *
WOJCICKI J ET AL: "EFFECT OF PAPAVERINE AND ATROPINE ON PHARMACOKINETICS OF PARACETAMOL ADMINISTERED ORALLY", POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY, POLISH ACADEMY OF SCIENCES INSTITUTE OF, PL, vol. 31, no. 3, 1997, pages 239 - 243, XP000974559, ISSN: 0301-0244 *
YAMAKITA H ET AL: "IN VITRO/IN VIVO EVALUATION OF TWO SERIES OF TA-5707F CONTROLLED RELEASE MATRIX TABLETS PREPARED WITHHYDROXYPROPYL METHYL CELLULOSE DERIVATIVES WITH ENTERO-SOLUBLE OR GEL-FORMATION PROPERTIES", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 18, no. 10, 1 October 1995 (1995-10-01), pages 1409 - 1416, XP000537682, ISSN: 0918-6158 *

Also Published As

Publication number Publication date
WO2002083110A2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
MX255941B (en) Isoxazoline derivative and herbicide comprising the same as active ingredient.
NO20040564L (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2002080969A1 (en) Remedies for infant chronic arthritis-relating diseases
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
WO2003074551A3 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
AU2002347910A1 (en) Methods and compositions for targeting proteins across the blood brain barrier
IL172423A0 (en) Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
DE50005529D1 (en) ORAL PHARMACEUTICAL FORMS FOR ADMINISTRATING A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
WO2004091591A3 (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
ITRM20030363A1 (en) COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM.
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
WO2001051072A3 (en) Antiparasitic agent
WO2002053149A3 (en) Medicament containing a polyamine as an active substance
MXPA02012857A (en) Use of a formulation made of or containing at least one dissimilated milk serum.
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
WO2002083110A3 (en) Animal model for evaluating analgesics
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2455274

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002727818

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002727818

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2002727818

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002727818

Country of ref document: EP